Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11) : A Pediatric Brain Tumor Consortium Study (PBTC-022) (pages 4180–4187)
Jason Fangusaro, Sridharan Gururangan, Tina Young Poussaint, Roger E. McLendon, Arzu Onar-Thomas, Katherine E. Warren, Shengjie Wu, Roger J. Packer, Anu Banerjee, Richard J. Gilbertson, Regina Jakacki, Amar Gajjar, Stewart Goldman, Ian F. Pollack, Henry S. Friedman, James M. Boyett, Larry E. Kun and Maryam Fouladi
Version of Record online: 19 SEP 2013 | DOI: 10.1002/cncr.28343
The combination of bevacizumab and irinotecan (CPT-11) was fairly well tolerated in children with recurrent central nervous system tumors. Most severe bevacizumab-related toxicities were rare, self-limiting, and manageable.